<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">TAK</journal-id>
<journal-id journal-id-type="hwp">sptak</journal-id>
<journal-id journal-id-type="nlm-ta">Ther Adv Cardiovasc Dis</journal-id>
<journal-title>Therapeutic Advances in Cardiovascular Disease</journal-title>
<issn pub-type="ppub">1753-9447</issn>
<issn pub-type="epub">1753-9455</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1753944712467394</article-id>
<article-id pub-id-type="publisher-id">10.1177_1753944712467394</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Letter to the Editor</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Prognostic value of cardiac troponin levels in infective endocarditis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Burton</surname><given-names>Mary Jane</given-names></name>
<aff id="aff1-1753944712467394">G.V. Sonny Montgomery VAMC, Medical Service, University of Mississippi Medical Center, Medicine/Infectious Diseases, 1500 East Woodrow Wilson Avenue, Jackson, MS 39216, USA</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Cockrell</surname><given-names>Joshua</given-names></name>
<aff id="aff2-1753944712467394">University of Mississippi Medical Center, Medicine, Jackson, MS, USA</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Holguin</surname><given-names>Geraldo</given-names></name>
<aff id="aff3-1753944712467394">University of Mississippi Medical Center, Medicine, Jackson, MS, USA</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Geraci</surname><given-names>Stephen</given-names></name>
<aff id="aff4-1753944712467394">University of Mississippi Medical Center, Medicine, Jackson, MS, USA</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-1753944712467394"><email>mary.burton2@va.gov</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2013</year>
</pub-date>
<volume>7</volume>
<issue>1</issue>
<fpage>45</fpage>
<lpage>46</lpage>
<permissions>
<copyright-statement>© The Author(s), 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<p>Recent analyses suggest that early surgery is associated with improved 6-month mortality in infective endocarditis (IE), emphasizing the need to identify patients who would benefit from early intervention. Although well established as a marker for myocardial injury and increased mortality in the setting of acute coronary syndromes [<xref ref-type="bibr" rid="bibr2-1753944712467394">Heidenreich <italic>et al</italic>. 2001</xref>], cardiac-specific troponins (Tn) have also been found to associate with clinical outcomes in other noncardiac diseases [<xref ref-type="bibr" rid="bibr1-1753944712467394">Dispenzieri <italic>et al</italic>. 2004</xref>]. Isolated reports suggest that elevated cardiac troponin I (TnI) and/or T (TnT) serum concentrations associate with poor prognosis in patients with IE. We performed a systematic review of this subject. An electronic literature search of the National Library of Medicine database using PubMed (all listings through 30 September 2012) was performed using the search terms ‘endocarditis’ and ‘troponin’, limited to human studies and English language articles. After excluding case reports (four) and letters to the editor (one), six original reports remained for inclusion in this analysis (<xref ref-type="table" rid="table1-1753944712467394">Table 1</xref>).</p>
<table-wrap id="table1-1753944712467394" position="float">
<label>Table 1.</label>
<caption>
<p>Summary of studies evaluating the relationship between cardiac markers and infective endocarditis.</p>
</caption>
<graphic alternate-form-of="table1-1753944712467394" xlink:href="10.1177_1753944712467394-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">Study design</th>
<th align="left">Marker(s)</th>
<th align="left">Mean age (years)</th>
<th align="left">Sample size eligible for analysis</th>
<th align="left">Deaths in sample (number) (%)</th>
<th align="left">Number in cohort (%)with elevated Tn</th>
<th align="left">Excluded predisposing conditions<sup><xref ref-type="table-fn" rid="table-fn1-1753944712467394">*</xref></sup></th>
</tr>
</thead>
<tbody>
<tr>
<td><xref ref-type="bibr" rid="bibr8-1753944712467394">Watkin <italic>et al</italic>. 2004</xref></td>
<td>Retrospective</td>
<td>TnI</td>
<td>51</td>
<td>15</td>
<td>2(13)</td>
<td>11(73)</td>
<td>Yes</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr4-1753944712467394">Purcell <italic>et al</italic>. 2008</xref></td>
<td>Retrospective</td>
<td>TnI</td>
<td>47</td>
<td>51</td>
<td>(26)</td>
<td>33(64)</td>
<td>No</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr7-1753944712467394">Tsenovoy <italic>et al</italic>. 2009</xref></td>
<td>Prospective</td>
<td>TnI</td>
<td>60</td>
<td>62</td>
<td>15(24)</td>
<td>35(57)</td>
<td>Yes</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr6-1753944712467394">Stancoven <italic>et al</italic>. 2011</xref></td>
<td>Retrospective</td>
<td>TnT, hs TnT</td>
<td>51</td>
<td>42</td>
<td>4(10)</td>
<td>25(56), 39(93)</td>
<td>No</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr5-1753944712467394">Shiue <italic>et al</italic>. 2010</xref></td>
<td>Retrospective</td>
<td>TnI, BNP</td>
<td>49</td>
<td>40, 45</td>
<td>NR</td>
<td>NR, 32(71)</td>
<td>No</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr3-1753944712467394">Kahveci <italic>et al</italic>. 2007</xref></td>
<td>Prospective</td>
<td>TnI, NT-pro-BNP</td>
<td>41<sup><xref ref-type="table-fn" rid="table-fn2-1753944712467394">$</xref></sup></td>
<td>38, 45</td>
<td>9(20)</td>
<td>NR</td>
<td>Yes</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1753944712467394">
<label>*</label>
<p>Conditions that may result in cardiac troponin release.</p>
</fn>
<fn id="table-fn2-1753944712467394">
<label>$</label>
<p>Reported median age of study population, range 9–75 years.</p>
</fn>
<fn id="table-fn3-1753944712467394">
<p>BNP, brain natriuretic peptide; hs-TnT, highly sensitive cardiac troponin T; NR- not reported; NT-pro-BNP, N-terminal pro-B-type natriuretic peptide; TnI, cardiac troponin I; TnT, cardiac troponin T</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The reviewed reports suggest Tn elevation commonly occurs in the setting of IE. Although inclusion criteria and assays differed between studies, the majority of patients (57–73%) with IE demonstrated elevated concentrations of cardiac markers. The initial investigation by Watkin and colleagues reported that 2/15 patients in his sample died of septic shock, both of whom had TnI ≥ 0.03 ng/ml [<xref ref-type="bibr" rid="bibr8-1753944712467394">Watkin <italic>et al</italic>. 2004</xref>]. The five studies that followed demonstrated that elevated levels of cardiac biomarkers (TnI, highly sensitivity cardiac troponin T, brain natriuretic peptide, N-terminal pro-B-type natriuretic peptide), associated with mortality, either as an individual primary endpoint and/or as a component of a composite outcome. However, the lack of Tn elevation in IE might correlate better with outcomes than detection of elevated serum levels. In the studies that evaluated negative predictive value (NPV), normal Tn levels had an NPV as high as 94% for mortality, myocardial abscess, and central nervous system events [<xref ref-type="bibr" rid="bibr4-1753944712467394">Purcell <italic>et al</italic>. 2008</xref>].</p>
<p>Studies in this analysis were uniformly limited by small sample sizes and single-center designs. Three studies originated from the same institution [<xref ref-type="bibr" rid="bibr4-1753944712467394">Purcell <italic>et al</italic>. 2008</xref>; <xref ref-type="bibr" rid="bibr5-1753944712467394">Shiue <italic>et al</italic>. 2010</xref>; <xref ref-type="bibr" rid="bibr6-1753944712467394">Stancoven <italic>et al</italic>. 2011</xref>], with potential overlap in patient population for two of the reports [<xref ref-type="bibr" rid="bibr4-1753944712467394">Purcell <italic>et al</italic>. 2008</xref>; <xref ref-type="bibr" rid="bibr5-1753944712467394">Shiue <italic>et al</italic>. 2010</xref>]. Prospective multicenter studies would be needed to determine if a clinically relevant, sufficiently robust relationship exists between cardiac biomarkers and major clinical outcomes in patients with IE.</p>
</body>
<back>
<fn-group>
<fn fn-type="conflict">
<label>Conflict of interest statement</label>
<p>The authors declare that they do not have any conflict of interest.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1753944712467394">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dispenzieri</surname><given-names>A.</given-names></name>
<name><surname>Gertz</surname><given-names>M.</given-names></name>
<name><surname>Kyle</surname><given-names>R.</given-names></name>
<name><surname>Lacy</surname><given-names>M.</given-names></name>
<name><surname>Burritt</surname><given-names>M.</given-names></name>
<name><surname>Therneu</surname><given-names>T.</given-names></name>
<etal/></person-group>. (<year>2004</year>) <article-title>Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis</article-title>. <source>J Clin Oncol</source> <volume>22</volume>: <fpage>3751</fpage>–<lpage>3757</lpage>.</citation>
</ref>
<ref id="bibr2-1753944712467394">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Heidenreich</surname><given-names>P.</given-names></name>
<name><surname>Alloggiamento</surname><given-names>T.</given-names></name>
<name><surname>Melsop</surname><given-names>K.</given-names></name>
<name><surname>McDonald</surname><given-names>K.</given-names></name>
<name><surname>Go</surname><given-names>A.</given-names></name>
<name><surname>Hlatkey</surname><given-names>M.</given-names></name>
</person-group> (<year>2001</year>) <article-title>The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: a meta-analysis</article-title>. <source>J Am Coll Cardiol</source> <volume>38</volume>: <fpage>478</fpage>–<lpage>485</lpage>.</citation>
</ref>
<ref id="bibr3-1753944712467394">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kahveci</surname><given-names>G.</given-names></name>
<name><surname>Bayrak</surname><given-names>F.</given-names></name>
<name><surname>Mutlu</surname><given-names>B.</given-names></name>
<name><surname>Bitigen</surname><given-names>A.</given-names></name>
<name><surname>Karaahmet</surname><given-names>T.</given-names></name>
<name><surname>Sonmez</surname><given-names>K.</given-names></name>
<etal/></person-group>. (<year>2007</year>) <article-title>Prognostic value of N-terminal pro-B-type natriuretic peptide in patients with active endocarditis</article-title>. <source>Am J Cardiol</source> <volume>99</volume>: <fpage>1429</fpage>–<lpage>1433</lpage>.</citation>
</ref>
<ref id="bibr4-1753944712467394">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Purcell</surname><given-names>J.</given-names></name>
<name><surname>Patel</surname><given-names>M.</given-names></name>
<name><surname>Khera</surname><given-names>A.</given-names></name>
<name><surname>De Lemos</surname><given-names>J.</given-names></name>
<name><surname>Forbess</surname><given-names>L.</given-names></name>
<name><surname>Baker</surname><given-names>S.</given-names></name>
<etal/></person-group>. (<year>2008</year>) <article-title>Relation of troponin elevation to outcome in patients with infective endocarditis</article-title>. <source>Am J Cardiol</source> <volume>101</volume>: <fpage>1479</fpage>–<lpage>1481</lpage>.</citation>
</ref>
<ref id="bibr5-1753944712467394">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shiue</surname><given-names>A.</given-names></name>
<name><surname>Stancoven</surname><given-names>A.</given-names></name>
<name><surname>Purcell</surname><given-names>J.</given-names></name>
<name><surname>Pinkston</surname><given-names>K.</given-names></name>
<name><surname>Wang</surname><given-names>A.</given-names></name>
<name><surname>Khera</surname><given-names>A.</given-names></name>
<etal/></person-group>. (<year>2010</year>) <article-title>Relationship of B-type natriuretric peptide with outcomes in patients with infective endocarditis</article-title>. <source>Am J Cardiol</source> <volume>106</volume>: <fpage>1011</fpage>–<lpage>1015</lpage>.</citation>
</ref>
<ref id="bibr6-1753944712467394">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stancoven</surname><given-names>A.</given-names></name>
<name><surname>Shiue</surname><given-names>A.</given-names></name>
<name><surname>Khera</surname><given-names>A.</given-names></name>
<name><surname>Pinkston</surname><given-names>K.</given-names></name>
<name><surname>Hashim</surname><given-names>I.</given-names></name>
<name><surname>Wang</surname><given-names>A.</given-names></name>
<etal/></person-group>. (<year>2011</year>) <article-title>Association of troponin T, detected with highly sensitive assay, and outcomes in infective endocarditis</article-title>. <source>Am J Cardiol</source> <volume>108</volume>: <fpage>416</fpage>–<lpage>420</lpage>.</citation>
</ref>
<ref id="bibr7-1753944712467394">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tsenovoy</surname><given-names>P.</given-names></name>
<name><surname>Aronow</surname><given-names>W.</given-names></name>
<name><surname>Joseph</surname><given-names>J.</given-names></name>
<name><surname>Kopacz</surname><given-names>M.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Patients with infective endocarditis and increased cardiac troponin I levels have a higher incidence of in-hospital mortality and valve replacement than those with normal cardiac troponin I levels</article-title>. <source>Cardiology</source> <volume>112</volume>: <fpage>202</fpage>–<lpage>204</lpage>.</citation>
</ref>
<ref id="bibr8-1753944712467394">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Watkin</surname><given-names>R.</given-names></name>
<name><surname>Lang</surname><given-names>S.</given-names></name>
<name><surname>Smith</surname><given-names>J.</given-names></name>
<name><surname>Elliot</surname><given-names>T.</given-names></name>
<name><surname>Littler</surname><given-names>W.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Role of troponin I in active infective endocarditis</article-title>. <source>Am J Cardiol</source> <volume>94</volume>: <fpage>1198</fpage>–<lpage>1199</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>